Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor

Dr. Joel Raskin joins ArrivoBio as Chief Medical Advisor. (Photo: Business Wire)

MORRISVILLE, N.C.–(BUSINESS WIRE)–Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor (CMA). With over 35 years of clinical, academic, and pharmaceutical research experience, Dr. Raskin brings deep expertise in mid and late-stage clinical development to the executive team at Arrivo.

“His wealth of experience working in clinical and commercial settings will play a pivotal role for our company as we bring these transformative therapies through the clinic. Importantly, Dr. Raskin is tasked with exploring the potential of SP-624 beyond major depressive disorder.”Post this

“We are honored to welcome Dr. Joel Raskin to our team as we continue to advance our novel therapies SP-624 and RABI-767,” said Steve Butts, CEO of Arrivo. “His wealth of experience working in clinical and commercial settings will play a pivotal role for our company as we bring these transformative therapies through the clinic. Importantly, Dr. Raskin is tasked with exploring the potential of SP-624 beyond major depressive disorder.”

During his two-decade tenure at Eli Lilly, Dr. Raskin played a crucial role in neuroscience drug development and commercialization, contributing significantly to areas such as mood and anxiety disorders, schizophrenia, dementia, migraine, and pain. He initiated the global lifecycle clinical trial program of Eli Lilly’s Cymbalta® and served as Senior Director for Alzheimer’s Disease diagnostics and therapeutics. His final role at Lilly involved leading the Reyvow® medical affairs team, the first medication in a new class of acute migraine medication in over twenty years.

“I’m truly excited to work with this great team at Arrivo,” said Dr. Raskin. “The chance to work on two new molecules that have the potential to change the treatment paradigms for several serious illnesses is a unique and amazing opportunity.”

Before joining Arrivo, Dr. Raskin was the CMO for MindCure, a company focused on developing and commercializing psychedelic drugs and digital treatments for mental health. He currently serves as a scientific reviewer for the Alzheimer’s Drug Discovery Foundation and an advisor to several neurosciences drug and device companies.

Dr. Raskin obtained his M.D. and FRCP(C) from the University of Toronto. Following the completion of his medical and psychiatry training, he worked as a leader in different clinical settings, including as Chief of Mental Health Services at Ajax and Pickering General, Head of the Depression Clinic and Lead Clinical Trial Psychiatrist for Mood Disorders at the Center for Addiction and Mental Health, University of Toronto. Over the course of his career, Dr. Raskin has published nearly 100 scientific articles.

About Arrivo BioVentures LLC

Working in partnership with investors, innovators, and pharmaceutical companies, Arrivo is always seeking solutions for unmet medical needs. Arrivo has a portfolio of diverse drug candidates with the potential to be first-in-class or best-in-class.

Arrivo is founded and led by a team that has built and sold four companies in the last 15 years. Two products are currently commercially available and helping patients. Arrivo is propelled forward by its insatiable curiosity and drive to solve complex problems and help millions of patients globally. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.